Advertisement

Topics

Better Buy: GlaxoSmithKline plc vs. Bristol-Myers Squibb

11:03 EDT 2 Jul 2017 | Topix

Big pharma stocks are arguably set to shine now that the threat of hard caps on drug prices is off the table. Global prescription drug sales, after all, are forecast to grow at a healthy 6.5% per year for the next five years running, according to EvaluatePharma.

Original Article: Better Buy: GlaxoSmithKline plc vs. Bristol-Myers Squibb

NEXT ARTICLE

More From BioPortfolio on "Better Buy: GlaxoSmithKline plc vs. Bristol-Myers Squibb"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Prescription Drugs
A prescription drug (also prescription medication or prescription medicine) is a licensed medicine that is regulated by legislation to require a medical prescription before it can be obtained. The term is used to distinguish it from over-the-counter drug...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...